

# Hospital Acquired Disease Testing Market Research Report 2023-2028: Growth, Top Companies Share, Size, and Forecast

*The HAls market is projected to reach a value of US\$ 27.7 Billion by 2028, expanding at a CAGR of 17.57% during 2023-2028.*

BROOKLYN, NY, USA, February 14, 2023 /EINPresswire.com/ -- IMARC Group has recently released a new research study titled "Hospital Acquired Disease Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2028", offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios.



Global Hospital Acquired Disease Testing Market to Reach US\$ 27.7 Billion by 2028, Modernization of Healthcare Infrastructure Impelling Growth

**Hospital Acquired Disease Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028**

[www.imarcgroup.com](http://www.imarcgroup.com)

[Sales@imarcgroup.com](mailto:Sales@imarcgroup.com)

+1-631-791-1145

Hospital Acquired Disease Testing Market Research Report 2023-2028

## Market Outlook:

The global [hospital acquired disease testing market size](#) reached US\$ 10.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US\$ 27.7 Billion by 2028, exhibiting a growth rate (CAGR) of 17.57% during 2023-2028. Hospital acquired disease, or nosocomial infection, is a name given to ailments that are caused by infectious toxin agents in hospitals and medical clinics. They can be categorized into urinary tract infection (UTI), bloodstream infections, surgical site infection (SSI), pneumonia, methicillin-resistant staphylococcus aureus (MRSA), etc. Some of the common reasons behind these types of hospital acquired diseases include lack of proper hygiene in the hospital setting, below-par maintenance, a rise in the prevalence of multi-drug resistant organisms (MDROs), etc. In several cases, they have also been traced to the own microbiome of the patient and prove extremely harmful to their health.

## Hospital Acquired Disease Testing Market Trends:

The rising incidences of nosocomial infections, such as catheter-related bloodstream infection (CRBSI) and central line-associated bloodstream infection (CLABSI) are primarily driving the hospital acquired disease testing market. Furthermore, the elevating focus among the leading manufacturers towards developing technologically advanced and efficient testing tools is also positively influencing the market growth. In line with this, the escalating adoption of innovative diagnostic techniques, including microarrays, real-time location systems (RTLs), polymerase chain reaction (PCR), and solid phase hybridization, is acting as another significant growth-inducing factor. Additionally, the expanding medical tourism industry and the increasing prevalence of modernized healthcare infrastructures are expected to propel the hospital acquired disease testing market over the forecasted period.

Get a PDF Sample for more detailed market insights: <https://www.imarcgroup.com/hospital-acquired-disease-testing-market/requestsampl>

Hospital Acquired Disease Testing Market 2023-2028 Competitive Analysis and Segmentation:

Competitive Landscape With Key Players:

The competitive landscape of the hospital acquired disease testing market has been studied in the report with the detailed profiles of the key players operating in the market.

Major Players Covered:

- Abbott Laboratories
- Alere, Inc.
- Becton, Dickinson and Company
- bioMérieux SA
- Hoffmann-La Roche Ltd.
- Hologic, Inc.
- QIAGEN
- Siemens Healthcare
- Diatherix Laboratories, Inc.
- Meridian Bioscience, Inc.
- Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
- Cepheid, Inc.

Report Segmentation:

The report has segmented the hospital acquired disease testing market on the basis of indication and region.

Based on Indication:

- UTI (Urinary Tract Infection)
- SSI (Surgical Site Infection)
- Pneumonia
- Bloodstream Infections
- MRSA (Methicillin-Resistant Staphylococcus Aureus)
- Others

#### Geographical Analysis:

- North America: (United States, Canada)
- Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa

Ask Analyst for Customization and Explore Full Report With TOC & List of Figures:

<https://www.imarcgroup.com/request?type=report&id=1128&flag=C>

#### Key Highlights of the Report:

- Market Performance (2017-2022)
- Market Outlook (2023-2028)
- Industry Trends
- Market Drivers and Success Factors
- The Impact of COVID-19 on the Global Market
- Value Chain Analysis
- Structure of the Global Market
- Comprehensive mapping of the competitive landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

#### Browse More Related Reports:

[Asia Pacific Hospital Acquired Disease Testing Market Report](#)

[United States Hospital Acquired Disease Testing Market Report](#)

#### About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their

businesses.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Elena Anderson  
IMARC Services Private Limited  
+1 6317911145  
[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/616928161>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.